Mednet Logo
HomeHematology
Hematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

Would you use routine PET scans after two cycles of R-CHOP to guide first-line treatment de-escalation in low-risk (aaIPI = 0) DLBCL patients?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Riverside Methodist Hospitals/OhioHealth

This phase III trial suggests that in very low-risk limited-stage DLBCL (aaIPI = 0), patients who achieve a negative PET after two cycles of R-CHOP can safely receive only four total cycles instead of six, with similar 3-year PFS (92% vs 89%) and less toxicity. However, the results apply to a highly...

How do you approach relapsed idiopathic HLH?

2 Answers

Mednet Member
Mednet Member
Hematology · Dalhousie University, Canada

This question is quite non-specific - the answer depends very much on the specific context (child, adult, relapsed after what treatment?) and as such, can only be answered in broad strokes.First, ensure that it is truly idiopathic – check EBV, CMV viral loads, and other viral/infectious triggers as ...

Do you initiate anticoagulation prophylaxis for pediatric patients with vascular compression secondary to solid tumor/lymphoma?

1 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · FibroFighters Foundation

It is an interesting question, but lacks critical details. Of course, most cancers are prothrombotic, and anticoagulation can have risks: Is it arterial or venous compression? Complete obstruction? Acute or chronic? Collaterals? Is it compromising an organ? Is thrombus seen, or is there blood flow?...

Prior to gender affirming surgery, do you hold estrogen (or convert to transdermal) to minimize postoperative VTE risk?

1 Answers

Mednet Member
Mednet Member
Hematology · BIDMC

I'd divide this into 2 sub-questions: what to do in a patient who has a history of thrombosis, and what to do in a patient without a history of thrombosis. In a patient with prior thrombosis, I would generally have them on indefinite anticoagulation alongside ongoing estrogen use. We know that trans...

Would you consider restarting IMID therapy in a patient with recent stroke while on IMID?

1 Answers

Mednet Member
Mednet Member
Hematology · Medical College of Wisconsin

This is a very good question, and practice likely differs across institutions as data is limited. The discussion below refers primarily to the immunomodulatory (IMID) agents lenalidomide and pomalidomide.As you are aware, IMID therapy is known to be associated with an increased risk for venous throm...

How do you approach ADT in patients with high-risk prostate cancer who have risk factors for VTE, such as Factor V Leiden?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology

My default recommendation for patients with localized, high-risk prostate cancer is to recommend the use of long-term ADT. This intervention seems to offer a relatively large, clinically significant OS benefit for patients in the modern era receiving dose-escalated ADT. This benefit has been observe...

Do you utilize D-dimer to inform anticoagulation duration in the treatment of VTE?

9
4 Answers

Mednet Member
Mednet Member
Hematology · University of Chicago

I had developed a policy during my last eight or ten years of practice evaluating how long patients should be treated after a thrombosis and I'd like to share some impressions over these years as well as conclusions that I reached. These conclusions formed the basis of my approach to this problem. I...

Do you routinely stop ESA when starting myelofibrosis patients on JAK inhibitor therapy?

1 Answers

Mednet Member
Mednet Member
Hematology · University of Chicago

The management of myelofibrosis with anemia is becoming increasingly nuanced, given the several JAK inhibitors available to us and the potential for add-on therapies! An excellent resource to consider regarding decision-making is Jain et al., PMID 39808793. Regarding this specific question at hand, ...

How do you manage the side effects of ropeginterferon alfa 2b for polycythemia vera patients?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Massachusetts General Hospital

Great question. Although ropeginterferon is better tolerated than other interferons, it is still associated with adverse events. If counts are controlled, I would recommend lowering the dose or spacing out the dosing interval, as that usually helps. For flu-like symptoms, I recommend pre-emptive man...

Can post op RT be omitted in a surgically repaired pathological fracture site in multiple myeloma if the patient will receive systemic therapy?

3
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

For extremities (e.g., the femur), if the pain is largely from structural instability, which resolves after surgical stabilization, then proceeding with systemic therapy without post-op RT would be very reasonable. On the other hand, if the patient is having persistent pain after surgery from the os...